Lijun Weng, M.D
Page 1 of 8
Lijun Weng, M.D.
CONTACT INFORMATION
E-mail: wengl09@gmail.com
Tel: (H) 718-428-2689
(M) 917-770-3288
CITIZENSHIP
U.S.A.
BOARD
1. American Board of Nuclear Medicine
2. Certification Board of Nuclear Cardiology
3. Certificate of complete 500 CT cases
Medical License
New York State (LIC NO. # 232264)
DEA # BW8871508
ACLS
BLS
CLINICAL ASSISTANT PROFESSOR OF RADIOLOGY
November 2009 - Present
SUNY, Stony Brook University Hospital
Department of Radiology, Nuclear Medicine
ATTENDING, CHIEF OF NUCLEAR MEDICINE
October 1, 2004 – Present
New York Methodist Hospital
Member of New York Presbyterian Hospital Healthcare
System,
Affiliated with Weill Medical College of Cornell
University
FELLOWSHIP
July 1, 2003-September 30, 2004
PGY-IV and PGY-V
Department of Radiology, Nuclear Medicine Division
Memorial Sloan-Kettering Cancer Center, New York City
CHIEF RESIDENT
July 1, 2002-June 30, 2003
PGY-III
Department of Radiology, Nuclear Medicine Division
Memorial Sloan-Kettering Cancer Center, New York City
RESIDENT
July 1, 2001-June 30,2002
PGY-II
Department of Radiology, Nuclear Medicine Division
Memorial Sloan-Kettering Cancer Center, New York City
INTERN
July 1, 2000 - June 30,2001 Department of Internal Medicine, Harbor Hospital
PGY-I
Baltimore, Maryland
Lijun Weng, M.D
Page 2 of 8
SENIOR RESEARCH ASSISTANT
February 1991–June 2000
The Johns Hopkins University, School of Medicine
Oncology Center, Division of Hematologic Malignancies
POST-DOCTORAL FELLOW
April 1988 – September 1990
University of California, San Francisco, Department of
Radiation Oncology
RESIDENT IN CHINA
August 1983 –April 1988
Dept. of Radiation Oncology, Shanghai Fu-Dan University
(prior Shanghai Medical University), Shanghai Cancer
Hospital, Shanghai, China
MEDICAL SCHOOL
October 1978 – August 1983 Medical Doctor Degree in Medicine, Shanghai Fu-Dan
University (former Shanghai Medical University), School
of Medicine, Shanghai, China
Research Projects
1.
Principal Investigator
Open Label Phase II Study of the Safety and Efficacy of
BMIPP (Iodofiltic Acid 123I) for Identification of Ischemic
Myocardium Using SPECT in Adults with Symptoms
Consistent with Acute Coronary Syndrome (ACS)
Sponsored by Molecularinsight Pharmaceuticals
2.
Co-Principal Investigator
Phase I/II Study of the Use of Vertebral Intracavitary Cement
and Samarium (153 Sm) for Painful Vertebral Metastases
PUBLICATIONS
1. ER. Cardoso, H. Ashamalla, LJ. Weng, B. Mokhtar, S. Ali, M.
Macedon, A.Guirguis
Percutaneous Tumor Curettage and Interstitial Delivery of
153
Samarium-EDTMP coupled with Kyphoplasty for Treatment of
Vertebral Metastases.
Journal of Neurousurgery: SPINE Apr 2009 Vol 10 No.4, p336342
2.
H. Ashamalla, E. Cardoso, M. Macedon, A.Guirguis, LJ. Weng,
S.Ali, B. Mokhtar, M. Ashamalla, and N. Panigrahi
Vertebral Intracavitary Cement and Samarium(VICS); A novel
technique for the treatment of painful vertebral metastasis
International Journal of Radiation Oncology Biology Physics.
Volume 72, Issue 1, Pages S486-S487, 2008
Lijun Weng, M.D
Page 3 of 8
PUBLICATIONS CONT.
3. Q. Chen, C.Tack, M. Morcos, M.Ruggiero, P.Schlossberg, J.
Fogel, LJ. Weng, and J. Farkas
Embolotherapy of Arterioportal Fistulas Cardiovasc Intervent Radiol.
2007 May 12
Steven D. Gore, Stephen Baylin, Carraway H, Carole B. Miller,
Michael Carducci, Michael Grever, Oliver Galm, T. Dauses, Judith E.
Karp, MA Rudek, M. Zhao, B. Douglas Smith1, Jasper Manning1,
Anchalee Jiemjit, George Dover, Abbie Mays, James Zweibel, Anthony
Murgo, Li-Jun Weng, and James Herman
Combined DNA Methyltransferase and Histone Deacetylase Inhibition
In The Treatment of Myeloid Neoplasms
Cancer Research, June 2006, 15;66912):6361-9
4.
5. Heiko Schöder, MD, Ariela Noy, MD, Mithat Gönen, PhD,
Lijun Weng, MD, David Green, BS, Steven M. Larson, MD, and
Henry W.D. Yeung, MD
Intensity of 18Fluorodeoxyglucose Uptake in PET Distinguishes
Between Indolent and Aggressive Non-Hodgkin’s Lymphoma,
Journal of Clinical Oncology, Vol 23, 21 July 2005
6. Li-Jun Weng M.D. and Heiko Schöder, M.D
Melanoma Metastasis to Testis Demonstrated with FDG PET/CT,
Clinical Nuclear Medicine, February 2005
7. Li-Jun Weng and Timothy Akhurst
Colon Cancer Metastasis to the Adrenal Gland Demonstrated with
FDG PET/CT, Clinical Nuclear Medicine, August 2004
8. Steven D. Gore, Li-Jun Weng, William D. Figg, Suoping Zhai, Ross
C. Donehower, George Dover, Michael R. Grever, Constance Griffin,
Louise B. Grochow, Anita Hawkins, Kathleen Burks, Yelena Zabelena
and Carole B. Miller
Impact of Prolonged Infusions of the Putative Differentiating Agent
Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute
Myeloid Leukemia, Clinical Cancer Research Vol. 8, 963-970, April
2002
9. Steven D. Gore, Li-Jun Weng, Suoping Zhai, William D. Figg, Ross
C. Donehower, George J. Dover, Michael Grever, Constance A.
Griffin, Louise B. Grochow, Eric K. Rowinsky, Yelena Zabalena,
Anita L. Hawkins, Kathleen Burks and Carole B. Miller
Impact of the Putative Differentiating Agent Sodium Phenylbutyrate
on Myelodysplastic Syndromes and Acute Myeloid Leukemia, Clinical
Cancer Research Vol. 7, 2330-2339, August 2001
Lijun Weng, M.D
Page 4 of 8
PUBLICATIONS CONT.
10. Li-Jun Weng (co 1st author w/ Kenneth H. Yu), Joseph A. DiGiusepe,
Shen Fu, Michael B. Kastan, Dvorit Samid, and Steven D. Gore
Phenylbutyrate-Induced G1 Arrest and Apoptosis in Myeloid Leukemia
Cells: Structure-Function Analysis, Leukemia, 13: 1243-1253, 1999
11. Li-Jun Weng ((co 1st author w/ Kenneth H. Yu), Shen Fu, and Steven
D. Gore
Augmentation of Phenylbutyrate-Induced Differentiation of Myeloid
Leukemia Cells Using all Trans-Retinoic Acid, Leukemia, 13, 1258-1265,
1999
12. Joseph A. DiGiusepe, Michael B. Kastan, Li-Jun Weng and Steven
D. Gore
Cytoprotective Effects of Hematopoietic Growth Factors on Primary
Human Acute Myeloid Leukemia are not Mediated Through Changes in
BCL-2, BAX, or p21 WAF/CIP1, In Vivo, 13:1-6, 1999
13. Steven D. Gore, Philip J. Burke, and Li-Jun Weng
Impact of Exogenous Growth Factors on Proliferation and
Chemosensitivity of Minimal Residual Acute Myeloid Leukemia.
Leukemia and Lymphoma, 29:339-350, 1998
14. Gore, S.D., Samid, D. and Weng, L-J
Impact of the Putative Differentiating Agents Sodium Phenylbutyrate and
Sodium Phenylacetate on Proliferation, Differentiation, and Apoptosis of
Primary Neoplastic Myeloid Cells, Clinical Cancer Research, 3: 17551762, 1997
15. S.D. Gore, L-J Weng, R.J. Jones, M. Zilcha, S. Piantadosi, and P.J.
Burke
Impact of In Vivo Administration of Interleukin-3 on Proliferation,
Differentiation, and Chemosensitivity of Acute Myeloid Leukemia,
Clinical Cancer Research, 1: 295-303, 1995
16. Gore, S.D., Amin, S., Weng L-J, and Civin, C.I.
Steel Factor Supports the Cycling of Isolated Human CD34+ Cells in the
Absence of Other Growth Factors, Experiment of Hematology, 23: 413421, 1995
17. Gore, S.D., Weng, L-J, Burke, P.J.
Identification of Growth Factor-Responsive Acute Myelogenous
Leukemia (AML) Based on Factor-Dependence for Survival and
Proliferation, Leukemia, 8(11): 1854-1863, 1994
Lijun Weng, M.D
Page 5 of 8
PUBLICATIONS CONT.
18. S.D. Gore, A.D. Donnenberg, B.A.Zehnbauer, L-J Weng and P.J.
Burke
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Given Concurrently with Induction Therapy for Acute Myelogenous
Leukemia (AML), Augments the Syndrome of T-Lymphocyte
Recovery, Leukemia, 8(3): 409-419, 1994
19. Gore, S.D., Weng, L-J and Burke, P.J.
Validation of Flow- Cytometric Determination of ki67 Expression as a
Measure of Growth Factor Response in Acute Myelogenous Leukemia,
Experimental Hematology, 21(13):1702-1708, 1993
ABSTRACTS
1. H. Ashamalla, E. Cardoso, L. Weng, S. Rafla, M. Macedon, N.
Panigrahi
Intervertebral administration of 153Samarium with Kyphoplasty for
vertebral metastases. Journal of Clinical Oncology, 2006 ASCO Annual
Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement),
2006: 13136
2. S. Iqbal, A. Khalid, L. Weng, M. Mansour
Assessing the Response to Drainage for Biliary Leak: Falsely positive
HIDA scan, American Journal of Gastroenterology) September 2006
(supplement)
3. L. Weng, H. Ashamalla, E. Cardoso, S. Rafla
The Use of Local Injection of 153Samajrium-EDTMP in Conjunction
with Kyphopl.asty for Palliation bone Metastasis, J. Nuc. Med. Vol 47
Supp 1, May 2006, 487p
4 L-J. Weng, H Schoder, A. Sinha, S.M. Larson and H.W. Yeung
FDG-PET in Lymphoma- Is There a Difference in 18F-FDG Uptake
Between Different Histological Subtypes? The 49th Annual Meting of
Nuclear Medicine, June 2002
5. Steve D. Gore, Li-Jun Weng, Kenneth Yu, and Shen Fu
Phenylbutyrate in Myeloid Malignancies: Relationship Between
Inhibition of Histone Deacetylase, Cytostasis and Differentiation
Proceeding of Leukemia Differentiation Annual Meeting in Canada,
October, 1999
Lijun Weng, M.D
ABSTRACTS
Page 6 of 8
CONT.
6. Gore, S.D., Weng, L-J, Griffin, C.A., Noe, D., Burks, K., Hawkins,
A., Smith, V., Dove, G., Grever, M., and Miller, C.B.
Impact of Prolonged Administration of the Putative Differentiation
Agent Sodium Phenylbutyrate on Hematopoiesis in Myelodysplastic
Syndrome and Acute Myeloid Leukemia, Blood 92 (Supplement 1),
633a, November 1998
7. Fu, S., Edenfild, J., Weng, L-J, and Gore, S.D.
Synergistic Induction of Apoptosis in Myeloid Leukemia Cells by
Combination of Two Putative Differentiation Inducers, Vesnarinone
and Sodium Phenylbutyrate, Proceeding of American Association
for Cancer Research, 1998
8. Weng, L-J, Yu, K., Fu, S., and Gore, S.D.
Synergy Between Retinoic Acid (RA) and The Putative Differentiation
Agent Sodium Phenylbutyrate (SPB) Promotes Maximal Cytostasis and
Differentiation of Myeloid Cells at Clinically Achievable Doses of SPB,
Blood 90(Supplement 1), 329a, 1997
9. Yu, K.H., Weng, L-J, Gore, S.D.
Augmentation of Phenylbutyrate (PB) induced differentiation of myeloid
leukemia cells using retinoic acid, proceeding of American association for
cancer research 38: 583a, 1997
10. Gore, S.D., Miller,C.B., Weng, L-J, Burks, K., Griffin, C.A., Chen,
T- L, Smith, V., Burke, P.J., Grever, M. and Rowinsky, E.K.,
Clinical Development of Sodium Phenylbutyrate (SPB) as a Putative
Differentiating Agent in Myeloid Malignancies, Anticancer Research
17: A28, 1997
11. Weng, L-J, Burke, P.J., and Gore, S.D.
Sodium Phenylbutyrate: Potential Differentiating Agent for Myeloid
Malignancies, Proceedings of American Association for Cancer Research
37: 2727a, 1996
12. Gore, S.D., Miller, C.B., Weng, L-J, Burke, K., Griffin, C.A., Chen,
TL, Burke, P.J.
Improved Hematopoiesis in Patients with Myelodysplastic Syndrome
(MDS) and Acute Myeloid Leukemia (AML) Following Administration of
The Putative Differentiation Agent Sodium Phenylbutyrate (SPB), Blood
88 (Supplement 1): 582a, 1996
Lijun Weng, M.D
ABSTRACTS
Page 7 of 8
CONT.
13. J.A. Digiuseppe, S.D. Gore, L-J Weng, and M.B. Kastan
Growth Factor Modulation of p21WAF1/CIP1 in Primary Acute Myeloid
Leukemia, Blood 88 (Supplement 1): 331a, 1996
14. Weng, L-J, Samid, D., Burke, P.J., Gore, S.D.
Irreversible Inhibition of Proliferation of Primary Acute Myeloid
Leukemic (AML) Cells by Phenylbutyrate (PB). Blood 84(10): 628a, 1994
15. Gore, S.D., Weng, L-J, Burke, P.J.
Biologic and Clinical Impact of Growth Factor (GF) Augmentation of
Post - Remission Chemotherapy for Acute Myeloid Leukemia (AML).
Blood 84(10): 582a, 1994
16. Gore, S.D., Jone, R.J., Weng, L-J, Cowan, K., Johnson, M.C., Zilcha,
M. and Burke, P.J.
In Vivo administration of Interleukin-3 (IL-3) During Remission Induction
Therapy for AML: Pleiotropic Effects on Drug Sensitivity. Blood 82
(supplement 1): 442a, 1993
17. Gore, S.D., Weng, L-J, and Burke, P.J.
Effect of Stem Cell Factor (SCF) on Proliferation of Blast Cells from
Patients with Acute Myeloid Leukemia (AML), Experimental Hematology
20(6): 208a, 1992
18. S.D. Gore, L.J. Weng, P.J. Burke and C.I. Civin
C-kit Expression Among Primitive Subsets of Human CD34 Bone Marrow
Progenitor Cells, Thirty-Forth Annual Meeting of American Society of
Hematology, Blood 80 (Supplement 1): 22a, November, 1992
19. S.D. Gore, L-J Weng, and P.J. Burke
Discordance Between Growth Factor Receptor Expression and
Response in Acute Myeloid Leukemia Blast Cell, Blood 80 ( Supplement
1), 437a, November, 1992
20. H.B. Stone, P.R. Stuffer, L-J Weng , K. Buss, H.Nguyen, and Y.H.
Luu
Thermal Dosimetry of 500KHZ + Water bath heating of Mouse Legs,
Proceeding of Radiation Research Society and North American
Hyperthermia Group, 1990
21. Li-Jun Weng, Karen K. Fu, and Kitty N. Lam
The Combined Effects of Cis-platin and Radiation at Acute and Low
Dose Rates on The Mouse Rectum, Proceeding of Radiation Research
Society and North American Hyperthermia Group, 1989
Lijun Weng, M.D
ABSTRACTS
Page 8 of 8
CONT.
22. Karen K. Fu, Li-Jun Weng and Kitty N. Lam
Acute and Late Effects of Concurrent Mitomycin C. and Continuous Low
Dose Rate Irradiation on The Mouse Skin and Rectum Proceeding of
Radiation Research Society and North American Hyperthermia Group,
1989